)

Overview

vTv’s Q3 net loss widens to $8.7 mln, driven by higher R&D expenses
Company completes $80 mln private placement to fund Phase 3 CATT1 trial

Result Drivers

PRIVATE PLACEMENT - $80 mln private placement strengthens balance sheet and supports Phase 3 CATT1 trial
R&D EXPENSES - Increased R&D spending reflects higher investment in cadisegliatin development

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $10.70

Operatin mln

Expenses

Q3 -$10.70

Operatin mln

g Income

Analyst Coverage

The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
The average consensus recommendation for the biotechnology & medical research peer group is “buy”
Wall Street’s median 12-month price target for vTv Therapeutics Inc is $35.50, about 31.7% above its November 5 closing price of $24.24

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

vTv Therapeutics Q3 net loss widens to $8.7 mln